Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
Merck & Co Inc MRK
News
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics — Update
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
Merck, Daiichi Sankyo Withdraw Application for Accelerated Approval of Lung Cancer Treatment
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
Merck, Eisai Get FDA OK of Welireg/Lenvima Combo in Kidney Cancer
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
Merck Phase 2b/3 Trial for Remigromig Meets Primary Endpoint
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
Moderna will reveal the data for its mRNA cancer vaccine next month. Here's why it matters.
Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
Moderna's personalized mRNA shot could reshape the fight against skin cancer - but it may also be overhyped
United States